Pretreating AML cells with the RIPK1 inhibitor necrostatin-1 or the RIPK3 inhibitor GSK’872 did not protect against LCL-805 cytotoxicity (Figure S8C). This evidence concerns the gene RIPK3 and acute myeloid leukemia.